Merck Animal Health Reports the Accessibility of Autogenous Vaccine for Avian Metapneumovirus Type B
Shots:
- The USDA has granted approval to Merck Animal Health for manufacturing & sale of Cambridge Technologies’ autogenous vaccine for avian metapneumovirus type B, targeting broilers, broiler breeders, layers & turkey breeders
- Merck Animal Health partnered with Cambridge Technologies in Apr 2024 to be the exclusive US sales agent for Cambridge's poultry vaccines
- Under the agreement, Cambridge utilized its production expertise and distribution while Merck offered its presence among customers
Ref: Merck Animal Health | Image: Merck Animal Health & Cambridge Technologies
Related News:- Merck Animal Health’s Nobivac NXT Canine Flu H3N2 Receives the USDA’s Approval for Canine Influenza
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
